Dr. Chao H. Huang
Claim this profileUniversity of Kansas Health System Saint Francis Campus
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
22 reported clinical trials
35 drugs studied
About Chao H. Huang
Education:
- Completed preparatory studies at Colegio Rosario, Porto Alegre, Rio Grande do Sul.
- Earned an MD from Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul.
Experience:
- Completed an Internship and Residency in Internal Medicine at Presbyterian Medical Center of the University of Pennsylvania Health System, Philadelphia, PA.
- Undertook a Clinical Fellowship in Hematology & Medical Oncology at Fox Chase Cancer Center and Temple University Hospital.
- Actively involved in teaching and mentoring at the University of Kansas Health System Saint Francis Campus, specializing in lung cancer and head and neck cancer.
Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
Stage II
2Non-Small Cell Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Chao H. Huang is currently running
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Chemotherapy + Immunotherapy vs. Immunotherapy
for Advanced Lung Cancer
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.
Recruiting2 awards Phase 3
More about Chao H. Huang
Clinical Trial Related6 years of experience running clinical trials · Led 22 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Chao H. Huang has experience with
- Pembrolizumab
- Carboplatin
- Pemetrexed
- Ramucirumab
- Biospecimen Collection
- Selpercatinib
Breakdown of trials Chao H. Huang has run
Lung Cancer
Non-Small Cell Lung Cancer
Parotid Gland Cancer
Relapse
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Chao H. Huang specialize in?
Is Chao H. Huang currently recruiting for clinical trials?
Are there any treatments that Chao H. Huang has studied deeply?
What is the best way to schedule an appointment with Chao H. Huang?
What is the office address of Chao H. Huang?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.